

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE  
SECURITIES EXCHANGE ACT OF 1934**

**For the Month of February 2026**

**Commission File Number: 001-37710**

---

**HUTCHMED (CHINA) LIMITED**  
(Translation of registrant's name into English)

---

**48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong**  
(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

---

---

**HUTCHMED (CHINA) LIMITED**

**Form 6-K**

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Announcement relating to notice of announcement of 2025 final results

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

HUTCHMED (CHINA) LIMITED

By: /s/ Johnny Cheng  
Name: Johnny Cheng  
Title: Chief Financial Officer

Date: February 6, 2026



## HUTCHMED to Announce 2025 Final Results

**Hong Kong, Shanghai & Florham Park, NJ — Friday, February 6, 2026:** HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2025 on Thursday, March 5, 2026 at 6:00 am Eastern Standard Time (EST) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT).

HUTCHMED management will host two webcast presentations for analysts and investors to discuss the final results, followed by Q&A sessions. The English webcast will be held on Thursday, March 5, 2026, at 8:00 am EST (1:00 pm GMT / 9:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT / 12:30 am GMT on Friday, March 6, 2026 (7:30 pm EST on Thursday, March 5, 2026).

Both webcasts will be available live via the website of the Company at [www.hutch-med.com/event/](http://www.hutch-med.com/event/). The presentation will be available to download shortly before the webcast begins. A replay will also be available on the website shortly after the event.

### About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: [www.hutch-med.com](http://www.hutch-med.com) or follow us on LinkedIn.

### CONTACTS

#### Investor Enquiries

+852 2121 8200 / [ir@hutch-med.com](mailto:ir@hutch-med.com)

#### Media Enquiries

FTI Consulting –

+44 20 3727 1030 / [HUTCHMED@fticonsulting.com](mailto:HUTCHMED@fticonsulting.com)

Ben Atwell / Tim Stamper

+44 7771 913 902 (Mobile) / +44 7421 898 348 (Mobile)

Brunswick – Zhou Yi

+852 9783 6894 (Mobile) / [HUTCHMED@brunswickgroup.com](mailto:HUTCHMED@brunswickgroup.com)

#### Panmure Liberum

*Nominated Advisor and Joint Broker*

Atholl Tweedie / Emma Earl / Rupert Dearden

+44 20 7886 2500

#### Cavendish

*Joint Broker*

Geoff Nash / Nigel Birks

+44 20 7220 0500

#### Deutsche Numis

*Joint Broker*

Freddie Barnfield / Jeffrey Wong / Duncan Monteith

+44 20 7260 1000